



## The 65th ASH Annual Meeting Abstracts

## POSTER ABSTRACTS

## 613.ACUTE MYELOID LEUKEMIAS: CLINICAL AND EPIDEMIOLOGICAL

**The Impact of Baseline Genetic Profile and Treatment on Hematological Toxicity in CEBPA-Mutated Acute Myeloid Leukemia**

Francesco Mannelli, MD<sup>1</sup>, Matteo Piccini<sup>2</sup>, Marco Frigeni, MD<sup>3</sup>, Giacomo Gianfaldoni<sup>4</sup>, Sara Bencini<sup>5</sup>, Silvia Salmoiraghi<sup>3</sup>, Barbara Scappini<sup>6</sup>, Benedetta Peruzzi<sup>7</sup>, Roberto Caporale<sup>7</sup>, Gaia Ciolli<sup>2</sup>, Laura Fasano<sup>2</sup>, Francesca Crupi<sup>2</sup>, Elisa Quinti<sup>2</sup>, Andrea Pasquini<sup>2</sup>, Sofia Pileri<sup>8</sup>, Fiorenza Vanderwert<sup>9</sup>, Giada Rotunno<sup>10</sup>, Fabiana Pancani<sup>11</sup>, Leonardo Signori<sup>11</sup>, Danilo Tarantino<sup>12</sup>, Chiara Maccari<sup>10</sup>, Vivian Paradiso<sup>2</sup>, Francesco Annunziato<sup>7</sup>, Orietta Spinelli<sup>13</sup>, Paola Guglielmelli, MDPH<sup>14</sup>, Alessandro Rambaldi, MD<sup>15</sup>, Alessandro Maria Vannucchi<sup>16</sup>

<sup>1</sup> CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy

<sup>2</sup> SOD Ematologia, Università di Firenze, AOU Careggi, Firenze, Italy

<sup>3</sup> Hematology and Bone Marrow Transplant Unit, ASST Papa Giovanni XXIII, Bergamo, Italy, Bergamo, Italy

<sup>4</sup> Hematology Unit, AOU Careggi, Florence, Italy

<sup>5</sup> Centro Diagnostico di Citofluorimetria e Immunoterapia, AOU Careggi, Florence, Italy

<sup>6</sup> Azienda Ospedaliero-Universitaria Careggi, Florence, ITA

<sup>7</sup> Centro Diagnostico di Citofluorimetria e Immunoterapia, AOU Careggi, Firenze, Italy

<sup>8</sup> Hematology Unit, Careggi Hospital, Firenze, Italy

<sup>9</sup> SOD Ematologia, Università di Firenze, AOU Careggi, Firenze, Italy; Centro Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), Firenze, Italy

<sup>10</sup> Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy

<sup>11</sup> Centro Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Firenze, Italy

<sup>12</sup> Department of Experimental and Clinical Medicine, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, University of Florence, Florence, Italy

<sup>13</sup> Hematology and Bone Marrow Transplant Unit, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy

<sup>14</sup> CRIMM, Center of Research and Innovation of Myeloproliferative Neoplasms, University of Florence, AOU Careggi, Florence, Italy

<sup>15</sup> Department of Oncology and Hematology, University of Milan and Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo BG, Italy

<sup>16</sup> Department of Experimental and Clinical Medicine, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, University of Florence, Firenze, Italy

**Background:** CEBPA-mutated acute myeloid leukemia (AML) is a separate entity in the updated WHO and ICC classifications. Previously identified by double mutations, the clinical profile and favorable outcome were correlated with in-frame mutations in bZIP domain. Beyond mutations recurrent in myeloid neoplasms (involving *TET2*, *FLT3*, *NRAS*), CEBPA-mutated AML is enriched in gene mutations (i.e., *GATA2*, *CSF3R*, *WT1*) rarely observed in CEBPA-wild type AML. No conclusive findings have been drawn for the prognostic impact of additional mutations. Of note, somatic *GATA2* mutations have been associated with invasive fungal infections in myeloid neoplasms. Although overall correlating with favorable prognosis, an unexpectedly high rate of treatment-related mortality (TRM) in CR has been described in a large multicenter study on intensively treated CEBPA-mutated patients (pts) (Schlenk et al Blood 2013;122(9):1576).

**Aims:** The aim of our study was to correlate baseline and treatment characteristics with the outcome and hematological toxicity in an intensively treated cohort of CEBPA-bZIP mutated AML pts.

**Methods:** Pts entering the study had a diagnosis of CEBPA-bZIP AML confirmed according to 2022 WHO and ICC criteria. Pts were characterized by next-Generation deep amplicon sequencing with Ion Torrent platform (ThermoFisher Scientific) covering a panel of 40 genes. Sequence alignment and filtering were performed by NextGENe version 2.4.2.1 (SoftGenetics). The first two chemotherapy cycles were categorized according to the delivery of an anthracycline (ANTHRAC) and cytarabine (ARA-C) at high dose (HDAC). The study was approved by the local institutional review board.

**Results:** From 2004 to 2023, 49 pts with *CEBPA*-bZIP mutated AML met the inclusion criteria at project study sites (Firenze, Bergamo). Their features are detailed in Table 1. CR rate was achieved in 45 of 49 pts (91.8%), with a DFS and OS of 74.3% and 82.4% at 5 y, respectively. Based on NGS, at least one additional mutation was identified in 18 (36.7%) pts (NGS+), the majority of them involving *GATA2* (n=14, 28.6%). As per treatment, 44 pts received at least two cycles, of which no (n=2, 4.6%), one (n=14, 31.8%), or two (n=28, 63.6%) ANTHRAC-containing cycles. As regarded HDAC, 19 (43.2%), 17 (38.6%) and 8 (18.2%) pts received no, one or two HDAC-containing cycles, respectively. No significant differences emerged for DFS or OS between NGS+ and NGS- groups (P=0.33 and 0.52, respectively). To gain insight into potential causes of toxicity during CR, we focused on hematopoietic recovery after induction and consolidation. NGS+ pts showed slower neutrophil (ANC) recovery (median, 22 days to >500/uL after induction and 25 days after consolidation) compared to NGS- group (19 days, P=0.018; 18 days P=0.058, respectively). Such effect was enhanced by treatment with ANTHRAC-containing cycles: NGS+ pts receiving two cycles required significantly longer time to recover from first consolidation cycle, both for ANC (30 days) and platelet count (34 days) vs 22 (P=0.012) and 27 (P=.010) days, respectively, of other categories (Figure 1). A proportion of 45.5% (5/11) NGS+/ANTHRAC-2 pts could not complete the planned chemotherapy program due to hematological toxicity compared to 19.3% (6/31, P=0.09) in other categories. No significant prolongation of recovery was observed for HDAC.

**Conclusions:** *CEBPA*-bZIP mutated AML is featured by high response rate and favorable outcome. Delayed hematopoietic recovery was observed in pts bearing additional mutations (especially *GATA2*) when treated with anthracyclines in first two cycles. Our findings suggest the cumulative dosage of anthracyclines should be limited in *CEBPA*-mutated/NGS+ patients to spare hematological toxicity on turn impairing the therapeutic plan.

**Disclosures Frigeni:** Jazz Pharmaceutical: Honoraria; **AbbVie:** Honoraria, Membership on an entity's Board of Directors or advisory committees. **Guglielmelli:** GSK: Speakers Bureau; **Novartis:** Other: Other member of advisory board, speaker at meeting, Speakers Bureau; **Abbvie:** Other: Other member of advisory board, speaker at meeting, Speakers Bureau. **Rambaldi:** Abbvie: Honoraria. **Vannucchi:** GSK: Honoraria; **BMS:** Honoraria; **Abbvie:** Honoraria; **Roche:** Honoraria; **AOP:** Honoraria; **Novartis:** Honoraria; **Incyte:** Honoraria.

Table 1

Pt characteristics	
n	49
Age, median (range)	46 (23-72)
WBC, x10 <sup>9</sup> /L, median (range)	9.45 (1.0-166)
Hb, g/dL, median (range)	10.5 (4.1-15.0)
Plt, x10 <sup>9</sup> /L, median (range)	29 (5-214)
PB blasts, %, median (range)	80 (7-100)
BM blasts, %, median (range)	80 (25-100)
Secondary AML (MDS, t-AML), n (%)	2 (4.1%)
Karyotype	
46,XX/46,XY	35 (71.3%)
del(9q)	4 (8.2%)
trisomy chr. 21	4 (8.2%)
lack of growth	4 (8.2%)
not available	2 (4.1%)
Gene mutations	
GATA2	14 (28.6%)
DNMT3A	5 (10.2%)
TET2	3 (6.1%)
CSF3R	2 (4.1%)
NRAS/KRAS	2 (4.1%)
Other	4 (8.2%)

Figure 1




Figure 1

<https://doi.org/10.1182/blood-2023-184845>